EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Advancing Pharma Innovation & Drug Development | Thermo Fisher Scientific | ISPE 2026 | Pharma Focus Asia
Senior Director, Head of Business Development APAC, Thermo Fisher Scientific
Koji Tanimoto is Senior Director of Biotech Account Management APAC at Thermo Fisher Scientifics Pharma Services Group Previously he served as Senior Director and Head of Business Development for Asia Pacific and Japan at Patheon also holding the title of Director at Patheon In Japan Since he led business development across both Patheons CDMO operations and Fisher Clinical Services clinical trial...
Articles
Why tier-2 and tier-3 cities are not included for clinical research
India is rapidly emerging as a global hub for clinical research with many international pharmaceutical companies and research organisations choosing the country as a site for their clinical trials
Research Insights
Efficacy of the Combination of Monoclonal Antibodies Against the SARS-CoV-2 Beta and Delta Variants
The pandemic of severe acute respiratory syndrome coronavirus SARSCoV is currently the biggest healthcare issue worldwide This study aimed to develop a monoclonal antibody against SARSCoV from B cells of recovered COVID patients which might have beneficial therapeutic purposes for COVID patients
Case Studies
Evaluation of A Sequencing Batch Reactor Sewage Treatment Rig For Investigating The Fate of Radioactively Labelled Pharmaceuticals: A Case Study of Propranolol
Abstract Pharmaceuticals are frequently detected in the aquatic environment and have potentially damaging effects Effluents from sewage treatment plants STPs are major sources of these substances The use of sequencing batch reactor SBR STPs involving cycling between aerobic and anoxic conditions to promote nitrification and denitrification is increasin
Techno Trends
Biogen Develops QALSODY®, the First Therapy to Treat a Rare, Genetic Form of ALS
Biogen has developed QALSODY a groundbreaking therapy for adults with amyotrophic lateral sclerosis linked to a mutation in the superoxide dismutase gene
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Advanced Drug Delivery Systems for Chronic Liver Disease Management
Jyothi U Menon received her PhD in Biomedical Engineering from the University of Texas (UT) Arlington and UT Southwestern Medical Center joint program. She completed her postdoctoral training at the University of Oxford, UK. She is currently an Associate Professor in the College of Pharmacy at the University of Rhode Island where her research focus is on targeted drug delivery systems to treat lung and liver diseases, and in vitro disease modeling.
Innovative Tool For Drug Design And Development
S.Subash awarded 2 best poster presentation awards and secured 1st place in Poster presentation. I published three articles in national and international peer reviewed journal. And, also attend many conferences to upgrade knowledge.
Machine Learning for New Drugs
Sneha Rai completed her Ph.D. from Computational and Structural Biology Lab., Department of Biological Sciences and Engineering at Netaji Subhas Institute of Technology (DU). She did masters in Bioinformatics from Banaras Hindu University and holds six years of bioinformatics research experience. Her area of interest includes structural bioinformatics, systems biology, protein/gene network analysis, data mining, computer aided drug designing, computational genomics, NGS data analysis, variant analysis and their clinical interpretation.
Venugopal Bhatia graduated from NSIT in 2019 with a B.E. in Biotechnology. During his undergraduate studies he was involved as an undergraduate researcher at the Computational and Structural Biology Laboratory and worked on two projects which were later published in Nature Scientific Reports and Elsevier Computational Biology and Chemistry. After a brief stint in industry, he's now pursuing his Master's at Yale.
Sonika Bhatnagar, Ph.D. (Biophysics), AIIMS works in the broad area of computational molecular biology. Her laboratory uses techniques of drug target selection, drug design & discovery, machine learning, and integrative genomics & proteomics towards Cardiovascular disease drug design and infectious disease therapeutics.
Metabolic Stability
Rajesh Sonti is working as an Assistant Professor since Feb 2020 in Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)-Hyderabad. He completed PhD from IISc, Bangalore and later worked as a post doc in University of Basel and EPFL-Lausanne for 6.5 years.
Venkata Rao Kaki is working as an Assistant Professor in Department of Chemical Sciences (medicinal chemistry/natural products),NIPER-Hyderabad. He completed PhD from Panjab university, Chandigarh. He has 4 years industrial and 8 years of academic experience.
Siva Nageswara Rao Gajulais pursuing PhD in Department of Pharmaceutical Analysis, NIPER-Hyderabad. He is working in the scientific areas:Drug Metabolism and Pharmacokinetics (DMPK), biomarkers and drug-drug interactions. He did M.S. (Pharm.) in department of pharmaceutical Analysisfrom NIPER-Ahmedabad.
Pursued M.S. (Pharm.), National Institute of Pharmaceutical Education and Research (NIPER)
Megha Sajakumar Pillai pursued M.S. (Pharm.) in department of pharmaceutical Analysis, NIPER-Hyderabad. She is currently pursuing PhD in NIPER-Ahmedabad.
How Ready are Cellulose Nanocrystals in Delivery of Anticanceragents?
Researcher, Donghua University
press releasesRead more...
Asia–US Clinical Data Collaboration Built on IHH's Clinical Data
Mitsui Co Ltd Mitsui Head Office Tokyo President and CEO Kenichi Hori has entered a service agreement with Oncoshot Pte Ltd Oncoshot on the utilization of Oncoshots proprietary clinical
Teijin, Teijin Regenet and Shinshu University Hospital Launch Joint Research to Strengthen CAR-T Cell Therapy Manufacturing Capabilities in Japan
Teijin Limited Teijin Regenet Co Ltd and Shinshu University Hospital today announced that they have entered into a joint research agreement regarding manufacturing technologies for cell and gene
VVMF, Australia’s First Viral Vector CDMO Receives TGA Manufacturing Licence
Viral Vector Manufacturing Facility Pty Ltd VVMF Australias first viral vector Contract Development and Manufacturing Organisation CDMO advises that the Therapeutic Goods Administration TGA
Oral insulin drug achieves a critical milestone
University of Sydney biotechnology spinout Endo Axiom is conducting its first study in human subjects to assess the safety and tolerability of different doses of oral insulin in healthy volunteers
Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies
Transcenta Therapeutics HKEX a global clinicalstage biopharmaceutical company with fully integrated capabilities in discovery RD and process development of antibodybased therapeutics
1cBio and Lee's Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio's PARP1 Inhibitor OC-3 for Oncology in Greater China
cBio a biopharmaceutical company focused on discovering and developing innovative therapies for serious and underserved conditions including oncology and metabolic diseases and Lees Pharmaceutical
EventsRead more...
14 - 15
Sep 202616th American DDF Summit
Omni Boston Hotel at the Seapo...
14 - 16
Sep 202615 - 17
Sep 2026COPD Drug Development Summit 2026
Street, Boston, MA 02210, USA
21 - 23
Sep 2026Cell & Gene Therapy World Conference
Miami, Florida, USA
21 - 23
Sep 2026Cancer R&D World Conference
Hilton Garden Inn Miami Dolphi...
22 - 23
Sep 2026PDA Advanced Parenteral Therapeutics & Quality Summit
Illume Hotel Taipei, Taiwan
22 - 24
Sep 2026InsurInnovator Connect Asia
Singapore
28 - 01
Sep 2026Discovery on Target 2026
Boston, MA, USA
LATEST NEWSRead more...
CordenPharma Expands Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Annually
CordenPharma is expanding its sterile injectable manufacturing capacity at its Caponago site in Milan Italy through a multiyear investment programme
Exegenesis Bio Enters into Collaboration with Modalis to Advance MDL-201 for Duchenne Muscular Dystrophy
Exegenesis Bio and Modalis Therapeutics have entered into a research collaboration and licence agreement to advance MDL an investigational treatment for Duchenne muscular dystrophy DMD
Schrödinger Forms Tectora Therapeutics to Advance Immunology and Inflammation Programmes
Schrdinger has announced the formation of Tectora Therapeutics The company was cofounded by Schrdinger New Enterprise Associates NEA and RA Capital Management
MannKind and Rose Pharma Partner to Develop Inhaled GLP-1 for Weight Management
MannKind and Rose Pharma have entered into a worldwide licensing and collaboration agreement to develop ROSE Technosphere an investigational inhaled GLP therapy for weight management
Rezubio Advances RZ-520 into Phase 1 Clinical Trial Following FDA and NMPA Clearances
Rezubio has announced the first cohort dosing in its Phase clinical trial of RZ following Investigational New Drug IND clearances from the US Food and Drug Administration FDA and Chinas National Medical
ZANVASTRO approved by FDA as first disease-modifying treatment for Alexander disease
Ionis Pharmaceuticals has received approval from the US Food and Drug Administration FDA for ZANVASTRO zilganersen to treat Alexander disease AxD in paediatric and adult patients